158 related articles for article (PubMed ID: 29435317)
21. Comparison of volume-reductive therapies for massive polycystic liver disease in autosomal dominant polycystic kidney disease.
Yang J; Ryu H; Han M; Kim H; Hwang YH; Chung JW; Yi NJ; Lee KW; Suh KS; Ahn C
Hepatol Res; 2016 Feb; 46(2):183-91. PubMed ID: 26190457
[TBL] [Abstract][Full Text] [Related]
22. Expanding the clinical application of the polycystic liver disease questionnaire: determination of a clinical threshold to select patients for therapy.
Barten TRM; Staring CB; Hogan MC; Gevers TJG; Drenth JPH;
HPB (Oxford); 2023 Aug; 25(8):890-897. PubMed ID: 37095030
[TBL] [Abstract][Full Text] [Related]
23. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis.
Rizk D; Jurkovitz C; Veledar E; Bagby S; Baumgarten DA; Rahbari-Oskoui F; Steinman T; Chapman AB
Clin J Am Soc Nephrol; 2009 Mar; 4(3):560-6. PubMed ID: 19261830
[TBL] [Abstract][Full Text] [Related]
24. The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.
D'Agnolo HMA; Casteleijn NF; Gevers TJG; de Fijter H; van Gastel MDA; Messchendorp AL; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JFM; Zietse R; Gansevoort RT; Drenth JPH
Am J Nephrol; 2017; 46(3):239-248. PubMed ID: 28881341
[TBL] [Abstract][Full Text] [Related]
25. Obstructive Sleep Apnea and Quality of Life: Comparison of the SAQLI, FOSQ, and SF-36 Questionnaires.
Silva GE; Goodwin JL; Vana KD; Quan SF
Southwest J Pulm Crit Care; 2016; 13(3):137-149. PubMed ID: 27738560
[TBL] [Abstract][Full Text] [Related]
26. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials.
Neijenhuis MK; Gevers TJ; Nevens F; Hogan MC; Torres VE; Kievit W; Drenth JP
Aliment Pharmacol Ther; 2015 Sep; 42(5):591-8. PubMed ID: 26129925
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.
Hogan MC; Masyuk T; Bergstralh E; Li B; Kremers WK; Vaughan LE; Ihrke A; Severson AL; Irazabal MV; Glockner J; LaRusso NF; Torres VE
Mayo Clin Proc; 2015 Aug; 90(8):1030-7. PubMed ID: 26166166
[TBL] [Abstract][Full Text] [Related]
28. Autosomal Dominant Polycystic Kidney Disease in which the Polycystic Liver Volume Was Reduced by Rigorous Blood Pressure Control.
Suwabe T; Ubara Y; Ikuma D; Mizuno H; Hayami N; Yamanouchi M; Sawa N
Intern Med; 2022 Jan; 61(1):49-52. PubMed ID: 34219109
[TBL] [Abstract][Full Text] [Related]
29. Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.
Chebib FT; Jung Y; Heyer CM; Irazabal MV; Hogan MC; Harris PC; Torres VE; El-Zoghby ZM
Nephrol Dial Transplant; 2016 Jun; 31(6):952-60. PubMed ID: 26932689
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Targets in Polycystic Liver Disease.
Masyuk TV; Masyuk AI; LaRusso NF
Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Polycystic Liver Disease: Impact on Patient-reported Symptom Severity and Health-related Quality of Life.
Duijzer R; Barten TRM; Staring CB; Drenth JPH; Gevers TJG
J Clin Gastroenterol; 2022 Oct; 56(9):731-739. PubMed ID: 35997709
[TBL] [Abstract][Full Text] [Related]
32. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.
Porath B; Gainullin VG; Cornec-Le Gall E; Dillinger EK; Heyer CM; Hopp K; Edwards ME; Madsen CD; Mauritz SR; Banks CJ; Baheti S; Reddy B; Herrero JI; Bañales JM; Hogan MC; Tasic V; Watnick TJ; Chapman AB; Vigneau C; Lavainne F; Audrézet MP; Ferec C; Le Meur Y; Torres VE; ; ; Harris PC
Am J Hum Genet; 2016 Jun; 98(6):1193-1207. PubMed ID: 27259053
[TBL] [Abstract][Full Text] [Related]
33. Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management.
Zhang ZY; Wang ZM; Huang Y
World J Hepatol; 2020 Mar; 12(3):72-83. PubMed ID: 32231761
[TBL] [Abstract][Full Text] [Related]
34. Treatment of symptomatic polycystic liver disease: transcatheter super-selective hepatic arterial embolization using a mixture of NBCA and iodized oil.
Wang MQ; Duan F; Liu FY; Wang ZJ; Song P
Abdom Imaging; 2013 Jun; 38(3):465-73. PubMed ID: 22743841
[TBL] [Abstract][Full Text] [Related]
35. Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease.
Bernts LHP; Neijenhuis MK; Edwards ME; Sloan JA; Fischer J; Smoot RL; Nagorney DM; Drenth JPH; Hogan MC
Surgery; 2020 Jul; 168(1):25-32. PubMed ID: 32402542
[TBL] [Abstract][Full Text] [Related]
36. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP
Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274
[TBL] [Abstract][Full Text] [Related]
37. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.
Griffiths J; Mills MT; Ong AC
BMJ Open; 2020 Jan; 10(1):e032620. PubMed ID: 31924636
[TBL] [Abstract][Full Text] [Related]
38. Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease.
Mizuno H; Hoshino J; Suwabe T; Sumida K; Sekine A; Oshima Y; Oguro M; Kunizawa K; Kawada M; Hiramatsu R; Hayami N; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K; Ubara Y
Case Rep Nephrol Dial; 2017; 7(3):108-111. PubMed ID: 29034246
[TBL] [Abstract][Full Text] [Related]
39. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.
Abu-Wasel B; Walsh C; Keough V; Molinari M
World J Gastroenterol; 2013 Sep; 19(35):5775-86. PubMed ID: 24124322
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
